New York-based Ohr Pharmaceutical named John Wroblewski, MD, to its ophthalmic scientific advisory board.
Dr. Wroblewski is a board-certified ophthalmologist with an expertise in diseases of the retina, macula and vitreous. He's a senior partner at Cumberland Valley Retina Consultants in Chambersburg, Pa.
The advisory board's retinal ophthalmology experts give guidance on clinical programs, regulatory issues and more. Ohr's leading drug candidate is Squalamine for neovascular ophthalmic clinical indications.
More Articles on Ophthalmology:
New Eyes in Las Vegas Hires Cornea Specialist Dr. Ksenia Stafeeva
Clearside Biomedical Appoints Dr. Glenn Noronha as Executive Vice President
Dr. John Ervin Elected President of Georgia Society of Ophthalmology